Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer

Duncan C. Gilbert*, Eva Serup-Hansen, Dorte Linnemann, Estrid Høgdall, Charles Bailey, Jeff Summers, Hanne Havsteen, Gareth J. Thomas

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftLetterForskningpeer review

62 Citationer (Scopus)

Abstract

Background: The majority (90%) of anal cancers are human papillomavirus (HPV)-driven, identified using immunochemistry for p16. Compared with HPV- patients, those with HPV+ disease generally show improved survival, although relapse rates around 25% indicate a need for further stratification of this group.

Methods: Using two cohorts of anal cancer, previously characterised for p16, we assessed the prognostic value of tumour-infiltrating lymphocytes (TILs).

Results: Tumour-infiltrating lymphocyte scores were used to stratify p16+ cases, where tumours with absent/low levels of TIL had a relapse-free rate of 63%, as opposed to 92% with high levels of TIL (log rank P=0.006).

Conclusions: Assessment of TIL adds to p16 status in the prognosis of anal cancer following chemo-radiotherapy and provides evidence of the clinical importance of the immune response.

OriginalsprogEngelsk
TidsskriftBritish Journal of Cancer
Vol/bind114
Sider (fra-til)134-137
Antal sider4
ISSN0007-0920
DOI
StatusUdgivet - 2016

Citationsformater